Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma.

@article{Bergsagel2013ImprovingOS,
  title={Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma.},
  author={P Leif Bergsagel and Mar{\'i}a Victoria Mateos and Norma Carmen Guti{\'e}rrez and S Vincent Rajkumar and Jes{\'u}s Fernando San Miguel},
  journal={Blood},
  year={2013},
  volume={121 6},
  pages={884-92}
}
Multiple myeloma (MM) is a heterogeneous disease with certain genetic features [e.g., t(4;14), del17p] associated with worse outcome. The introduction of thalidomide, lenalidomide, and bortezomib has dramatically improved the outlook for patients with MM, but their relative benefit (or harm) for different genetic patient subgroups remains unclear. Unfortunately, the small number of patients in each subgroup frequently limits the analysis of high-risk patients enrolled in clinical trials… CONTINUE READING